


EARNINGS RELEASE

Q1, 2020 (May 4th, 2020)



Seoul Viosys IR materials can be downloaded from the company website

- 1) IR Book : Visit Seoul Viosys website (<http://www.seoulviosys.com/en/ir/data/>)
- 2) Financial Statements : Visit Dart System (<http://englishdart.fss.or.kr/>) > Click "XBRL Financial Statements" on the top-of menu > Click "XBRL Search" on the left side > Enter the company code # (092190)
- 3) You can also access other disclosed documents of Seoul Viosys on this site.

Disclaimer

This presentation material may contain forward-looking statements, as defined in the safe harbor provisions of KOSDAQ Disclosure Regulation.

These forward-looking statements reflect Seoul Viosys' current views with respect to future events and financial performance, and are subject to certain risks and uncertainties, which could cause actual results to differ materially from those anticipated.

Although Seoul Viosys believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, it can give no assurance that its expectations will be attained.

Seoul Viosys undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. All financial numbers are consolidated basis unless stated otherwise.



EARNINGS RELEASE Q1, 2020

CONTENTS

Chapter 01. Q1, 2020 Results

Chapter 02. Q2, 2020 Guidance

Chapter 03. Appendix

Chapter 01.

Q1, 2020 Results


1. Sales and Earnings
2. Investments and Expenses
3. Production and CAPEX
4. Balance Sheet

1. Sales and Earnings

- Q1 Sales Increased by 10% YoY to 87 Bil. UV LED Increased 15% YoY, 18% QoQ
- Q1 EBITDA Margin Ratio Increased 7ppt YoY to 19.2% amid Some Players Are Making Continued Loss


Sales Unit: Billion KRW, %

Visible
UV & Others



Earnings Unit: Billion KRW, %

Operating Profit
EBITDA




2. Investments and Expenses

- Q1 R&D Investments to Sales Decreased 6.5 ppt YoY (Amount Decreased 32% YoY and 18% QoQ)
- SG&A Expenses Decreased 4.5ppt YoY due to Continued Cost Reduction Efforts

R&D Investments

Unit: Billion KRW, %


- ◆ % of R&D Investments to Sales
- R&D Investments



Expenses

Unit: Billion KRW, %

- SG&A Expenses
- Depreciation Expenses
- ◆ % of SG&A Expenses to Sales



3. Production and CAPEX




Chapter 01. 2020 Results

- Some Facility Transfer to VINA in Q4, '19 Completed in Q1, '20. Capacity Up and Utilization Down
- CAPEX Decreased due to advanced Investment in '19 on Core Productions such as UV and MicroLED

Production

Unit: 1,000 wafer (2" equivalent), %


- Utilization Ratio
- Production Result
- Capacity



CAPEX

Unit: Billion KRW, %

- % of CAPEX to Sales
- CAPEX




Note) The above production performance index is the average value for the quarter, which is somewhat different from the end of the quarter.

4. Balance Sheet



Chapter 01. 2020 Results

- Current Ratio Increased 10.1 ppt YoY and Debt to Equity Ratio Reached below 200%. Net Debt Ratio Dramatically Decreased by 66.4 ppt YoY which Shows Enhanced Financial Stability
- Inventory Turnover is 56 Days, which is ½ or less of competitors'



Chapter 02.


Q2, 2020 Guidance

1. Sales Guidance

1. Sales Guidance

Chapter 02. Q2, 2020 Guidance

- Violeds Demand Expected to Increase due to Worldwide Change of Awareness regarding Viruses
- Suggesting Q2 Sales Guidance of 90 billion to 95 billion won, 4-9% QoQ and 0-6% YoY Increase



Chapter 03.

Appendix

1. Condensed Financials

1. Condensed Financials



Chapter 03. APPENDIX

(Mii. KRW)	2020.Q1	2019.Q4	2019.Q3	2019.Q2	2019.Q1	2018.Q4	2018.Q3	2018.Q2	2018.Q1	2019	2018	2017	2016	2015	2014
[Income Statement]															
Sales	86,901	91,548	90,668	89,618	78,805	99,786	109,849	88,346	88,432	350,640	386,412	386,651	278,137	316,983	297,594
COGS	71,061	70,255	72,949	67,080	70,508	84,225	83,066	63,952	74,100	280,792	305,344	315,955	226,818	238,712	242,009
COGS (%)	81.8%	76.7%	80.5%	74.9%	89.5%	84.4%	75.6%	72.4%	83.8%	80.1%	79.0%	81.7%	81.5%	75.3%	81.3%
Gross Profit	15,840	21,294	17,719	22,538	8,297	15,560	26,783	24,393	14,332	69,848	81,069	70,696	51,319	78,271	55,585
Gross Profit (%)	18.2%	23.3%	19.5%	25.1%	10.5%	15.6%	24.4%	27.6%	16.2%	19.9%	21.0%	18.3%	18.5%	24.7%	18.7%
SG&A	13,154	14,254	15,041	14,832	15,465	22,693	15,430	13,170	13,077	59,592	64,370	41,297	39,947	49,977	40,745
Operating Profit	2,687	7,040	2,677	7,707	- 7,168	- 7,133	11,353	11,224	1,255	10,256	16,699	29,399	11,372	28,294	14,840
Operating Profit (%)	3.1%	7.7%	3.0%	8.6%	-9.1%	-7.1%	10.3%	12.7%	1.4%	2.9%	4.3%	7.6%	4.1%	8.9%	5.0%
Pre-tax Profit	1,038	894	4,197	5,891	- 8,103	- 11,359	5,852	10,615	- 166	2,879	4,943	16,995	5,501	19,479	532
Net Profit	255	1,080	3,140	5,992	- 8,759	- 8,456	3,826	9,044	- 813	1,454	3,601	13,039	4,124	16,807	12,258
[Balance Sheet]															
Total Assets	603,066	579,081	555,433	558,368	480,921	414,013	455,801	345,395	354,076	579,081	555,433	558,368	480,921	414,013	455,801
Current Assets	156,829	137,985	109,376	117,087	85,281	77,367	111,538	108,621	113,282	137,985	109,376	117,087	85,281	77,367	111,538
Cash and Equivalents	5,298	6,272	9,348	4,378	6,903	3,095	1,645	1,093	1,545	6,272	9,348	4,378	6,903	3,095	1,645
Inventory	67,770	54,943	55,620	47,991	44,620	42,112	43,326	19,316	18,638	54,943	55,620	47,991	44,620	42,112	43,326
Non-current Assets	446,237	441,096	446,057	441,281	395,640	336,646	344,263	236,774	240,793	441,096	446,057	441,281	395,640	336,646	344,263
Total Liabilities	399,499	391,587	393,176	400,590	329,566	253,046	286,756	199,347	218,077	391,587	393,176	400,590	329,566	253,046	286,756
Current Liabilities	287,711	274,105	258,287	291,551	191,144	143,753	217,985	133,757	148,603	274,105	258,287	291,551	191,144	143,753	217,985
Non-Current Liabilities	111,789	117,481	134,889	109,039	138,422	109,293	68,770	74,216	69,475	117,481	134,889	109,039	138,422	109,293	68,770
Total Equity	203,567	187,494	162,257	157,778	151,354	160,967	169,046	146,048	135,999	187,494	162,257	157,778	151,354	160,967	169,046

“We hope that our success story based on significant R&D efforts will set a good example for young entrepreneurs and small businesses trying to achieve their dreams”

